Neurocrine Biosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
38.9%projected annual EPS growth
Analyst Coverage
27analysts covering
FY Revenue (est.)
$3.9Bnext fiscal year
FY EPS (est.)
$10.19next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
INGREZZA Net Product Sales Quarterly656.9MTarget: $2.7 Billion to $2.8 Billion (Full-Year 2026 Guidance)
CRENESSITY (crinecerfont) Net Product Sales Quarterly153MTarget: Annualized run-rate exceeding $600 Million
Non-GAAP R&D Expenses Annually272MTarget: $1.11 Billion to $1.16 Billion (Full-Year 2026 Guidance)
Watch Items
- Soleno Therapeutics Acquisition IntegrationTrigger: Transaction closing expected in Q2 2026Action: Monitor post-close commercial integration of VYKAT XR (diazoxide choline) for Prader-Willi syndrome and update full-year expense guidance.
- Phase 3 Pipeline Readouts (osavampator and direclidine)Trigger: Topline data readouts expected in 2027Action: Track clinical trial progress for osavampator in Major Depressive Disorder and direclidine in schizophrenia to validate long-term pipeline value.
- INGREZZA Pricing PressureTrigger: Expected mid-single-digit net pricing pressure in 2026Action: Evaluate gross-to-net discount trends and formulary access investments during quarterly earnings releases.
Research as of 2 Sep 2026